Temozolomide chemoradiation then adjuvant temozolomide (Stupp)
Checked 2026-09-09
Newly diagnosed glioblastoma, age 70 or under, performance status 0-2 (hypofractionated variants for older patients)
One cycle
every 28 days × 6 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Temozolomide (concurrent) Oral alkylating chemotherapy | 75 mg/m² daily for 42 days with radiotherapy 60 Gy in 30 fractions | Oral | D1-28 | weeks 1-6 |
Temozolomide (adjuvant) Oral alkylating chemotherapy | 150 mg/m² cycle 1, then 200 mg/m² | Oral | D1-5 | cycles 1-6, starting 4 weeks after radiotherapy |
Radiotherapy | 2 Gy per fraction, 5 days a week | Radiotherapy | D1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26 |
Cycles
6 weeks concurrent, then 6 adjuvant cycles (12 with TTFields)
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- PJP prophylaxis during concurrent phase (lymphopenia); benefit largest with MGMT promoter methylation.
- EF-14: adding TTFields to adjuvant temozolomide extended median OS from 16.0 to 20.9 months.
Used in
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.